232 related articles for article (PubMed ID: 27127913)
1. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
2. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
Trementino L; Zilio M; Marcelli G; Michetti G; Barbot M; Ceccato F; Boscaro M; Scaroni C; Arnaldi G
Endocrine; 2015 Sep; 50(1):154-61. PubMed ID: 25500791
[TBL] [Abstract][Full Text] [Related]
3. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
4. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
[TBL] [Abstract][Full Text] [Related]
5. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
7. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Polenta B; Spinello M; Boscaro M; Arnaldi G
Pituitary; 2015 Feb; 18(1):60-7. PubMed ID: 24482099
[TBL] [Abstract][Full Text] [Related]
8. Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.
Barbot M; Guarnotta V; Zilio M; Ceccato F; Ciresi A; Daniele A; Pizzolanti G; Campello E; Frigo AC; Giordano C; Scaroni C
Endocrine; 2018 Oct; 62(1):207-214. PubMed ID: 29980915
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide: a review of its use in Cushing's disease.
McKeage K
Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
[TBL] [Abstract][Full Text] [Related]
10. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
13. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Boscaro M; Arnaldi G
Pituitary; 2015 Jun; 18(3):359-65. PubMed ID: 24952218
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MacKenzie Feder J; Bourdeau I; Vallette S; Beauregard H; Ste-Marie LG; Lacroix A
Pituitary; 2014 Dec; 17(6):519-29. PubMed ID: 24287689
[TBL] [Abstract][Full Text] [Related]
15. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
[TBL] [Abstract][Full Text] [Related]
17. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
[TBL] [Abstract][Full Text] [Related]
18. Effective long-term treatment of Cushing's disease with pasireotide: a case report.
Lu L; Duan L; Jin Z; Lu Z; Gu F
Endocr Pract; 2013; 19(4):e92-6. PubMed ID: 23512383
[TBL] [Abstract][Full Text] [Related]
19. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
20. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".
Pivonello R; Arnaldi G; Scaroni C; Giordano C; Cannavò S; Iacuaniello D; Trementino L; Zilio M; Guarnotta V; Albani A; Cozzolino A; Michetti G; Boscaro M; Colao A
Endocrine; 2019 Jun; 64(3):657-672. PubMed ID: 30968338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
